Drugs /

anti-erbb3 monoclonal antibody ktn3379

Back to Drugs List

Overview

NCI Definition [1]:
A monoclonal antibody directed against the human epidermal growth factor receptor ErbB3 (Her3) with potential antineoplastic activity. Anti-ErbB3 monoclonal antibody KTN3379 binds to and prevents ligand binding to ErbB3, which may inhibit ErbB3-dependent phosphatidylinositol-3 kinase (PI3K)/Akt signaling and may lead to the inhibition of cellular proliferation and differentiation. ErbB3, a member of the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases, is frequently overexpressed in a variety of solid tumors and its overexpression generally correlates with poor prognosis and tumor resistance.

Clinical Trials

View Clinical Trials for anti-erbb3 monoclonal antibody ktn3379

Anti-erbb3 monoclonal antibody ktn3379 has been investigated in 1 clinical trial, of which 0 are open and 1 is closed. Of the trial investigating anti-erbb3 monoclonal antibody ktn3379, 1 is phase 1 (0 open).

BRAF V600E, ERBB2 Amplification, and ERBB2 Mutation are the most frequent biomarker inclusion criteria for anti-erbb3 monoclonal antibody ktn3379 clinical trials.

Breast carcinoma, gastric carcinoma, and malignant solid tumor are the most common diseases being investigated in anti-erbb3 monoclonal antibody ktn3379 clinical trials [2].

Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Anti-Erbb3 Monoclonal Antibody Ktn3379
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating anti-erbb3 monoclonal antibody ktn3379 and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
ktn3379
NCIT ID [1]:
C113333

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.